SGLT2 (sodium-glucose cotransporter 2) inhibitors produce a distinctive pattern of benefits
on the evolution and progression of cardiomyopathy and nephropathy, which is …

Abstract Aim The “2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure”
replaces the “2013 ACCF/AHA Guideline for the Management of Heart Failure” and the …

Hypoxia, characterized by reduced oxygen concentration, is a significant stressor that affects
the survival of aerobic species and plays a prominent role in cardiovascular diseases. From …

Background: Empagliflozin reduces the risk of cardiovascular death or hospitalization for
heart failure in patients with heart failure and a reduced ejection fraction, with or without …

2020 Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk
Reduction in Patients With Type 2 Diabetes: A Report of the American College of …

SGLT2 inhibitors are antihyperglycemic drugs that protect kidneys and the heart of patients
with or without type 2 diabetes and preserved or reduced kidney function from failing. The …

Anemia is common in patients with chronic kidney disease and is associated with a high
burden of morbidity and adverse clinical outcomes. In 2012, Kidney Disease: Improving …

Background In patients with type 2 diabetes, inhibitors of sodium–glucose cotransporter 2
(SGLT2) reduce the risk of a first hospitalization for heart failure, possibly through glucose …

Importance Dapagliflozin has been shown to reduce the risk of cardiovascular death or
worsening heart failure (HF) in patients with chronic HF and reduced ejection fraction …

Background SGLT2 inhibition decreases albuminuria and reduces the risk of kidney disease
progression in patients with type 2 diabetes. These benefits are unlikely to be mediated by …